Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial

Category Primary study
Conference22nd International Congress of the Society for Melanoma Research
Year 2026
This article has no abstract
Epistemonikos ID: 445c6be06eed7636e5d92122c09939083e7aded4
First added on: Mar 07, 2026